TIGIT and lung carcinoma: Other phase I/II studies are underway in lung cancer exploring combinations of humanised IgG1 anti-TIGIT (Domvanalimab/AB154) in combination with anti-PD1 agent Zimberelimab (EDGE-Lung, NCT05676931) and anti-adenosine agent Etrumadenant (AB928) (NCT04791839).